Celebrating 20 Years of Training in Botox®, Aesthetic Medicine
and Medical Weight Management

Start Training Now
IAPAM Logo
Aesthetic Medicine Symposium - November 14-16 in Scottsdale, AZ! Register Now
IAPAM Logo
Aesthetic Medicine Symposium — Nov 14–16, Scottsdale, AZ Register Now →
Home » Medical Weight Management Library Trulicity® vs Ozempic®

Trulicity® vs Ozempic®

A comprehensive comparison of Trulicity® (dulaglutide) and Ozempic® (semaglutide)

Glucagon-like peptide-1 receptor agonists (GLP‑1 RAs) have reshaped type 2 diabetes care and weight-management programs. Two of the most requested weekly injectables are Trulicity® (dulaglutide) and Ozempic® (semaglutide). Both improve glycemic control, support weight reduction, and offer cardiovascular benefits in appropriate patients—yet they differ in molecule, device design, dose range, efficacy, side-effect profile nuances, and labeling.
Trulicity vs Ozempic

Key Takeaways

  • Both Trulicity® and Ozempic® are once‑weekly GLP‑1 RAs for type 2 diabetes; Ozempic® generally provides greater A1C lowering and weight loss at comparable doses, while Trulicity® offers a simple single‑use autoinjector and broad cardiovascular outcomes data.
  • Neither Trulicity® nor Ozempic® is FDA‑approved specifically for chronic weight management; semaglutide for weight management is marketed separately as Wegovy®. Use products within their labels and local regulations.
  • Start low, go slow: careful dose titration, GI side‑effect counseling, and a standardized 10–12 week review improve adherence and outcomes. Screen for contraindications (MTC/MEN2), retinopathy risk (with Ozempic®), pancreatitis history, gallbladder disease, and significant GI motility disorders.
  • For clinics: align on device training, touchpoint timelines, nutrition/behavioral support, and privacy‑compliant progress tracking; transparent pricing and access navigation reduce drop‑off.

What they are and what they’re approved for

Trulicity® (dulaglutide)

  • Class: GLP‑1 receptor agonist
  • Indication: adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes; has cardiovascular benefit data in patients with or at risk for cardiovascular disease.
  • Not approved for chronic weight management.
Ozempic® (semaglutide injection)
  • Class: GLP‑1 receptor agonist
  • Indication: adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes; reduces risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
  • Not approved for chronic weight management; semaglutide specifically approved for that use is Wegovy®.
Register Now
AESTHETIC MEDICINE SYMPOSIUM | November 14-16, 2026 | Scottsdale, Arizona
Learn to Build a Profitable Practice in just 3-days!

Includes hands-on Botox® injection training led by board-certified dermatologists on live models in a clean clinic setting

Up To 33.5 CMES | 3-Day Hands-On | Save up to $3,605 with IAPAM Membership
“Very educational, love the hands-on and plenty of resources and materials.” — B. Chang, DO
AESTHETIC MEDICINE SYMPOSIUM | November 14-16, 2026 | Scottsdale, Arizona
Learn to start a profitable practice in just 3-days!
Up to 33.5 CMEs | 3-Day Hands-On | Save up to $3,605 with IAPAM Membership!
“Very educational, love the hands-on and plenty of resources and materials.” — B. Chang, DO
Register Now

Dosing and administration at a glance

Trulicity®

  • Once weekly, single‑use, ready‑to‑inject pen with hidden needle.
  • Typical titration: 0.75 mg → 1.5 mg → 3.0 mg → 4.5 mg weekly as tolerated and needed for control.
Ozempic®
  • Once weekly, multi‑dose pen; user attaches a new pen needle for each injection and dials the dose.
  • Typical titration: 0.25 mg weekly (starter dose; not for glycemic control) → 0.5 mg → 1 mg → up to 2 mg weekly as needed/tolerated.

Practical notes for clinics

  • Teach consistent injection day, site rotation, and what to do if a dose is missed (follow the product label).
  • Store and handle per label; confirm in‑use room‑temperature time limits with staff and patients.
  • Provide sharps containers and written “what to expect” guidance.

Comparative efficacy: A1C and weight

Glycemic control

  • Head‑to‑head data (e.g., SUSTAIN‑7) show Ozempic® generally lowers A1C more than comparable dulaglutide doses used in Trulicity®, though individual response varies.
  • Typical A1C reduction ranges (monotherapy or add‑on) often fall around 1.0–1.9% depending on baseline A1C and dose for both agents.
Weight change
  • Both reduce weight; Ozempic® tends to produce greater average weight loss than Trulicity® at comparable weekly doses in clinical trials.
  • Remind patients: weight change is dose‑dependent, gradual, and enhanced by nutrition, physical activity, sleep, and behavioral support.

Cardiovascular outcomes

  • Trulicity®: The REWIND trial demonstrated a reduction in major adverse cardiovascular events (MACE), including in many patients without established cardiovascular disease.
  • Ozempic®: The SUSTAIN‑6 trial demonstrated a reduction in MACE in adults with type 2 diabetes and high cardiovascular risk.
  • Counseling tip: cardiovascular benefit is a class strength; therapy choice should align with individual risk profiles and comorbidities.

Safety profiles and key differences to counsel

Class effects shared by Trulicity® and Ozempic®
  • GI: nausea, vomiting, diarrhea, constipation; typically transient and dose‑related. Titrate slowly, encourage small/low‑fat meals, and hydration.
  • Hypoglycemia: uncommon alone; risk increases with sulfonylureas/insulin—consider dose adjustments of those agents.
  • Gallbladder disease: monitor for biliary symptoms.
  • Pancreatitis: rare; discontinue if suspected.
  • Renal considerations: dehydration from GI losses can worsen renal function; monitor in at‑risk patients.
  • Boxed warning (class): risk of thyroid C‑cell tumors in rodents. Contraindicated with personal/family history of medullary thyroid carcinoma (MTC) or MEN2. Not studied for type 1 diabetes.
  • Pregnancy and lactation: generally avoid; plan contraception and preconception counseling.

Considerations more prominent with Ozempic®

  • Diabetic retinopathy complications: rapid A1C improvement was associated with increased retinopathy complications in trial data; screen and coordinate with eye care in patients with existing retinopathy.
  • Gastric emptying: as with the class, counsel peri‑procedural fasting and follow current anesthesia/endo society guidance on pre‑op holds in patients undergoing sedation.

Considerations for Trulicity®

  • Device simplicity (single‑use, hidden needle) may enhance adherence in needle‑averse patients or those with dexterity challenges.

Who might be a better fit for each?

Consider Trulicity® when

  • A simple single‑use autoinjector is preferred.
  • Broad CV outcomes data across a wide risk spectrum is valued.
  • Patient prioritizes steadier GI tolerability at conservative titration (individual responses vary).

Consider Ozempic® when

  • Maximizing A1C reduction and weight loss potential is a priority.
  • Patient is comfortable using a multi‑dose pen and pen needles.
  • There is established atherosclerotic cardiovascular disease and a desire to use a semaglutide‑based regimen
Always personalize by comorbidities (retinopathy, GI motility issues, gallbladder history), concomitant meds, access/cost, and patient preferences.

Practical tips for medical aesthetic and weight‑management clinics

Intake and screening

  • Document diabetes history, A1C, comorbidities, thyroid/MEN2 history, pancreatitis/gallbladder history, eye disease, pregnancy plans, and current meds.
Titration roadmap
  • Pre‑schedule dose increases at 4‑week intervals if tolerated; set a check‑in cadence (week 2, 6, 10).
Side‑effect playbook
  • Provide a GI “survival guide” (meal size, protein focus, fluids, fiber, ginger/peppermint, when to pause titration).
  • Create escalation rules: persistent vomiting, dehydration, severe abdominal pain, visual changes, or signs of pancreatitis warrant prompt evaluation.
Lifestyle integration
  • Provide a GI “survival guide” (meal size, protein focus, fluids, fiber, ginger/peppermint, when to pause titration).
  • Create escalation rules: persistent vomiting, dehydration, severe abdominal pain, visual changes, or signs of pancreatitis warrant prompt evaluation.

Operations

  • Train on both devices; keep demo pens; standardize teaching scripts and missed‑dose policies.
  • Ensure privacy‑compliant progress photos/metrics; avoid implying weight‑loss indications beyond the label.
  • Build a coverage toolkit: prior authorization templates, financial counseling, alternatives if a product is out of stock.

Access, cost, and coverage

Setting expectations

Both Trulicity® and Ozempic® help lower blood sugar and support weight reduction. We start low and increase slowly so your body adjusts. Most people notice appetite and portion changes in a few weeks; A1C changes show up at your next lab check.

If nausea occurs

Small, protein‑forward meals and steady fluids help. If symptoms last more than a few days or you can’t keep fluids down, contact us—don’t increase your dose until you’re comfortable again.

On label clarity
Ozempic® and Trulicity® are approved for type 2 diabetes. If your main goal is weight management without diabetes, Wegovy® is the semaglutide product approved for that use..

Frequently asked questions

Which works better for weight loss?

On average in trials, Ozempic® produced more weight loss than Trulicity® at comparable doses, but individual response varies. Sustainable habits remain essential.

Can I switch between them?

Yes, with a clinician‑directed cross‑titration plan and monitoring for side effects and glycemic changes.

How long will I need to stay on therapy?

These are chronic therapies for ongoing benefit. Stopping often reverses gains; discuss long‑term plans.

Can I drink alcohol?

In moderation if your clinician agrees, but alcohol can worsen GI symptoms and affect glucose.

Quality and safety checklist for clinics

  • Confirm indications and contraindications at each visit.
  • Record brand, lot, dose, and education provided.
  • Standardize follow‑ups at 4–6 weeks for tolerance and at 12 weeks for efficacy reassessment.
  • Coordinate with primary care/endocrinology for labs, complications, and comorbidity management.

Conclusion

Trulicity® and Ozempic® are effective, once‑weekly GLP‑1 options for adults with type 2 diabetes, with Ozempic® typically delivering greater average A1C and weight reductions and Trulicity® offering a highly user‑friendly device and robust cardiovascular data. Your best choice aligns clinical goals, safety considerations, patient preferences, and access. Pair either therapy with structured education and lifestyle support to turn early momentum into durable metabolic health.
Disclaimer: The information provided here is for general knowledge only and should not be considered medical advice. For any questions or concerns about your health or medications, please consult your physician or healthcare provider. They are best equipped to provide guidance specific to your medical needs.

Related Articles

Hands-On Aesthetic Medicine Training

Hands-On BOTOX® Training in Scottsdale, Arizona

Gain the confidence to start seeing patients right away.

November 14–16, 2026 Scottsdale, Arizona AMA PRA Category 1 CME

Attend IAPAM’s comprehensive AMA PRA Category 1 CME BOTOX® training weekend and learn the clinical and business foundations for aesthetic practice growth.

✓Hands-on BOTOX® injection training in a clean, multi-million-dollar medspa—not a hotel.
✓Live models and product are provided so you can focus on learning with expert instructors.
✓Build foundations in five non-invasive treatments, with an optional GLP-1 weight-management or business add-ons.
Explore Botox Training Options →
Hands-on Botox training with a live model in Scottsdale

Click the image to explore upcoming BOTOX® training.

Aesthetic Medicine + GLP-1 Training

Secure your seat at 50% off

Terms and conditions apply. Offer expires October 31.